Thermal ablation is heating tumors so hot that the tumor cells die. It has been studied in many forms, including microwave, laser, high-intensity focused ultrasound, and cryotherapy (freezing below -20 C). Radiofrequency thermal ablation or radiofrequency ablation (RFA) has emerged as the most commonly used technology for thermal ablation in the bone, liver, kidney, lung, heart, breast, lymph nodes, nerve ganglia, and soft tissue.
Scientists at The Methodist Hospital Research Institute in Houston received a research grant from the Cancer Prevention Research Institute of Texas (CPRIT) today to develop the first molecular image guided system to diagnose and treat small-cell peripheral lung cancer in one sitting.
Image-guided radiofrequency ablation (RFA), a minimally invasive cancer treatment which can be performed in the outpatient setting, significantly reduced the level of pain experienced by cancer patients with bone (osseous) metastases, limiting the need for strong narcotic pain management, and supporting improved patient frame of mind, according to results of an American College of Radiology Imaging Network (ACRIN) study published online in the journal Cancer.
The Center for Digestive Care at NewYork-Presbyterian Hospital/Weill Cornell Medical Center has been established with a mission to provide high-quality patient care, research and education for all aspects of digestive disease.
Celsion Corporation, a leading oncology drug development company, today provided an update on the progress of its pivotal ThermoDox® Phase III “HEAT” trial for the treatment of hepatocellular carcinoma (HCC), the most common form of primary liver cancer. Following recent regulatory approvals in China, Malaysia, Thailand and the Philippines, the study is now enrolling patients in eleven countries, with the majority of clinical sites located in the Asia Pacific region where HCC is most prevalent.
At the 95th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) from November 29 to December 3 at McCormick Place in Chicago, Siemens Healthcare will introduce its comprehensive portfolio for imaging in interventional oncology at booth #825, East Building/Lakeside Center, Hall D.
Colorectal carcinoma is one of the most common cancers in the world. Approximately one in four of these patients have metastases at diagnosis, liver being the most common site involved. Although historically it was considered that liver metastases meant a very poor prognosis, today, due to improved systemic therapy, many patients will be candidates for local hepatic treatments such as surgery or less aggressive radiofrequency ablation.
Registration is now open for the Society of Interventional Radiology's "Image-guided Interventional Oncology (IO) Therapies" Webinar, which will provide the latest updates on percutaneous and transcatheter treatment of liver tumors, kidney tumor ablation and lung tumor ablation.
While studying how the heart is formed, scientists at the University of Pennsylvania School of Medicine serendipitously found a novel cellular source of atrial fibrillation (AF), the most common type of abnormal heart beat.
Celsion Corporation and Yakult Honsha Co., Ltd. announced today that the first patient has been enrolled and treated in Japan as part of Celsion’s global Phase III ThermoDox HEAT trial for the treatment of hepatocellular carcinoma (HCC), the most common form of primary liver cancer.
Celsion Corporation announced today that it has completed a critical regulatory step in the countries of China and Japan to rapidly enroll patients in its global Phase III ThermoDox trial for the treatment of Hepatocellular Carcinoma (HCC), also known as primary liver cancer.
Celsion Corporation announced today that it has received approval from the regulatory agencis in the Philippines and Malaysia for its Pivotal Phase III primary liver cancer Clinical Trial Application.
Celsion Corporation announced today that it has received official approval from China’s State Food and Drug Administration (“SFDA”) for its Clinical Trial Application for ThermoDox that permits Celsion to include Chinese clinical trial sites in its Phase III ThermoDox HEAT trial for the treatment of primary liver cancer, also known as hepatocellular carcinoma (HCC).
Four-time Olympic gold medal winner and three-time WNBA Most Valuable Player Lisa Leslie is teaming with Covidien, a leading global provider of healthcare products, to launch an educational program and Web site, www.MyLiverCancerOptions.com, that provide information to help patients and their families understand the treatment options available to manage liver cancer.
Radiofrequency ablation, a procedure that uses heat to shrink the tissue of the soft palate, is an effective and minimally invasive procedure that can be used to treat patients who snore.
MedWaves, Inc. announces ongoing investigational studies to determine the effectiveness of its microwave ablation system for treating soft tissue lesions, such as tumors, in liver and lung. The studies using MedWaves' AveCure(TM) microwave coagulation-ablation system, which includes a generator and probe/antenna (FDA 510(k) cleared and CE Mark certified), are showing promising results.
Virginia Interventional and Vascular Associates (VIVA) and its parent group, Radiologic Associates of Fredericksburg (RAF) Ltd., announce that Victor J. D'Addio, M.D., FACS, has joined the practice. Dr. D'Addio is a board-certified vascular surgeon. Together, the practice offers streamlined services for vascular patients and referring physicians -- from office-based vascular testing to minimally invasive treatments and traditional surgery.
By injecting multiwalled carbon nanotubes (MWCNTs) into tumors and heating them with a quick, 30-second zap of a laser, a multi-institutional team of researchers from the Wake Forest University School of Medicine (WFUSOM), Wake Forest University Center for Nanotechnology and Molecular Materials, Rice University, and Virginia Polytechnic Institute and State University has developed a new type of therapy that effectively kills kidney tumors in nearly 80% of treated mice. Researchers say that the findings, which were published in the Proceedings of the National Academy of Sciences of the United States of America, suggest a potential future cancer treatment for humans.
Researchers at Wake Forest University School of Medicine have destroyed prostate cancer tumors in mice by injecting them with specially-coated, miniscule carbon tubes and then superheating the tubes with a brief zap of a laser.
A team of researchers working at the MR-Center of the University Children's Hospital in Zürich has completed a pilot study using transcranial MR-guided focused ultrasound to treat 10 patients with neuropathic pain.
By injecting man-made, microscopic tubes into tumors and heating them with a quick, 30-second zap of a laser, scientists have discovered a way to effectively kill kidney tumors in nearly 80 percent of mice. Researchers say that the finding suggests a potential future cancer treatment for humans.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.